CN108578563A - 一种用于治疗糖尿病肾病的中药 - Google Patents
一种用于治疗糖尿病肾病的中药 Download PDFInfo
- Publication number
- CN108578563A CN108578563A CN201810316959.4A CN201810316959A CN108578563A CN 108578563 A CN108578563 A CN 108578563A CN 201810316959 A CN201810316959 A CN 201810316959A CN 108578563 A CN108578563 A CN 108578563A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- diabetic nephropathy
- traditional chinese
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 26
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 244000197580 Poria cocos Species 0.000 claims abstract description 15
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 15
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 12
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000219781 Pueraria montana var. lobata Species 0.000 claims 4
- 241000405414 Rehmannia Species 0.000 claims 3
- 235000006533 astragalus Nutrition 0.000 abstract description 15
- 241000405911 Rehmannia glutinosa Species 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 244000248557 Ophiopogon japonicus Species 0.000 abstract description 11
- 210000000952 spleen Anatomy 0.000 abstract description 11
- 241001061264 Astragalus Species 0.000 abstract description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 10
- 229940010454 licorice Drugs 0.000 abstract description 10
- 210000004072 lung Anatomy 0.000 abstract description 10
- 210000004233 talus Anatomy 0.000 abstract description 10
- 210000003734 kidney Anatomy 0.000 abstract description 9
- 244000046146 Pueraria lobata Species 0.000 abstract description 8
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract description 7
- 210000002216 heart Anatomy 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 230000035922 thirst Effects 0.000 abstract description 5
- 208000004880 Polyuria Diseases 0.000 abstract description 4
- 210000001124 body fluid Anatomy 0.000 abstract description 4
- 239000010839 body fluid Substances 0.000 abstract description 4
- 230000035619 diuresis Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 206010012735 Diarrhoea Diseases 0.000 abstract description 2
- 238000010791 quenching Methods 0.000 abstract description 2
- 230000000171 quenching effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 208000001431 Psychomotor Agitation Diseases 0.000 abstract 1
- 206010038743 Restlessness Diseases 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 244000132619 red sage Species 0.000 description 10
- 241000202807 Glycyrrhiza Species 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 241000045403 Astragalus propinquus Species 0.000 description 5
- 239000002398 materia medica Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000003359 percent control normalization Methods 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于治疗糖尿病肾病的中药,属于中药技术领域。本发明用于治疗糖尿病肾病的中药,由以下重量份的原料组分制成:熟地黄20‑60份、黄芪20‑55份、丹参12‑24份、麦冬15‑26份、葛根25‑35份、茯苓20‑30份、灸甘草10‑18份。本发明用于治疗糖尿病肾病的中药配方中,熟地黄益心血补肾水,黄芪补肺健脾,两者共为君药;丹参养神定志、通利关脉、麦冬养阴润肺、益胃生津、清心除烦,两者共为臣药;葛根清热解表、升阳止泻、茯苓健脾利湿,两者共为佐药;灸甘草为使药,调和诸药。全方合用,共奏补肺健脾益肾,补气生血、消渴利水之功效。
Description
技术领域
本发明涉及中药技术领域,具体涉及一种用于治疗糖尿病肾病的中药。
背景技术
糖尿病肾病是由糖尿病引起的一种严重的和危害性较大的慢性并发症,由糖尿病引起的微血管病变而导致的肾小球硬化,属于中医“消渴”,“水肿”的范畴,患者一旦出现微量蛋白尿,若不进行及时有效的治疗,肾功能逐渐减退直至衰竭。目前西医治疗多从饮食控制,强化血糖控制、降压、调整脂代谢等方面着手,或是采用透析,肾移植等治疗手段,虽然有一定的疗效,但是给患者带来沉重的经济负担。中医理论认为,糖尿病肾病的病机以气阴虚损为本,以淤血、水湿、痰浊为标,病位在脾、肺、肾,消渴日久、伤津耗气、阴阳两虚是糖尿病肾病的根本病因。中医药在防治糖尿病肾病方面显示出独特的优势,在延缓病情进展及控制疾病的恶化方面效果更佳。
发明内容
本发明的目的是为了克服现有技术中的问题,提供一种用于治疗糖尿病肾病的中药。
本发明提供了一种用于治疗糖尿病肾病的中药,由以下重量份的原料组分制成:熟地黄20-60份、黄芪20-55份、丹参12-24份、麦冬15-26份、葛根25-35份、茯苓20-30份、灸甘草10-18份。
较佳地,由以下重量份的原料组分制成:熟地黄49份、黄芪48份、丹参21份、麦冬17份、葛根26份、茯苓22份、灸甘草11份。
较佳地,由以下重量份的原料组分制成:熟地黄56份、黄芪36份、丹参21份、麦冬23份、葛根25份、茯苓24份、灸甘草15份。
较佳地,由以下重量份的原料组分制成:熟地黄37份、黄芪46份、丹参17份、麦冬25份、葛根31份、茯苓28份、灸甘草16份。
较佳地,上述用于治疗糖尿病肾病的中药的剂型为溶液剂、片剂、丸剂、颗粒剂、冲剂或者胶囊。
与现有技术相比,本发明的有益效果是:本发明用于治疗糖尿病肾病的中药,方中熟地黄益心血补肾水,黄芪补肺健脾,两者共为君药;丹参养神定志、通利关脉,麦冬养阴润肺、益胃生津、清心除烦,两者共为臣药;葛根清热解表、升阳止泻,茯苓健脾利湿,两者共为佐药;灸甘草为使药,调和诸药。全方合用,共奏补肺健脾益肾、补气生血、消渴利水之功效。
本发明的原料组分分别具有以下的功效与作用:
熟地黄:《药品化义》中记载,熟地,藉酒蒸熟,味苦化甘,性凉变温,专入肝脏补血。因肝苦急,用甘缓之,兼主温胆,能益心血,更补肾水。《本经逢原》中记载,熟地黄,假火力蒸晒,转苦为甘,为阴中之阳,故能补肾中元气。
黄芪:《本草汇言》中记载,“黄芪,补肺健脾,实卫敛汗,驱风运毒之药也。故阳虚之人,自汗频来,乃表虚而腠理不密也,黄芪可以实卫而敛汗;伤寒之证,行发表而邪汗不出,乃里虚而正气内乏也,黄芪可以济津以助汗;贼风之疴,偏中血脉而手足不随者,黄芪可以荣筋骨”。《本草便读》中记载,黄芪善达表益卫,温分肉,肥腠理,使阳气和利,充满流行,自然生津生血,故为外科家圣药,以营卫气血太和,自无瘀滞耳。”
丹参:《本草正》中记载,丹参,心、脾、肝、肾血分之药。《日华子本草》中记载,丹参,养神定志,通利关脉,治冷热劳,骨节疼痛,四肢不遂;排脓止痛,生肌长肉;破宿血,补新生血。
麦冬:《医学衷中参西录》言其:“能入胃以养胃液,开胃进食,更能入脾以助脾散精于肺,定喘宁嗽。”中医认为,麦冬味甘、微苦,性微寒,归胃、肺、心经,有养阴润肺、益胃生津、清心除烦的功效,用于肺燥干咳、阴虚痨嗽、喉痹咽痛、津伤口渴、内热消渴、心烦失眠、肠燥便秘等症。《本草分经》称麦冬“润肺清心、泻热生津、化痰止呕、治嗽行水”。
葛根:《药性论》中记载,“治天行上气,呕逆,开胃下食,主解酒毒,止烦渴。熬屑治金疮,治时疾解热。”《本经》中记载,“主消渴,身太热,呕吐,诸痹,起阴气,解诸毒。”。
茯苓:用于小便不利、水肿等症。茯苓利水渗湿、而药性平和,利水而不伤正气,为利水渗湿要药。
灸甘草:补脾和胃、益气复脉。
具体实施方式
下面对本发明的具体实施方式进行详细描述,但应当理解本发明的保护范围并不受具体实施方式的限制。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
本发明提供的一种用于治疗糖尿病肾病的中药,由以下重量份的原料组分制成:熟地黄49份、黄芪48份、丹参21份、麦冬17份、葛根26份、茯苓22份、灸甘草11份。
上述原料按照常规方法,制成中药汤剂,每日1剂,分早晚两次服用,每次煎服150ml,2周为一个疗程,连续治疗3个疗程。
实施例2:
本发明提供的一种用于治疗糖尿病肾病的中药,由以下重量份的原料组分制成:熟地黄37份、黄芪46份、丹参17份、麦冬25份、葛根31份、茯苓28份、灸甘草16份。
上述原料按照常规方法,制成中药汤剂,每日1剂,分早晚两次服用,每次煎服150ml,2周为一个疗程,连续治疗3个疗程。
实施例3:
本发明提供的一种用于治疗糖尿病肾病的中药,由以下重量份的原料组分制成:熟地黄56份、黄芪36份、丹参21份、麦冬23份、葛根25份、茯苓24份、灸甘草15份。
上述原料按照常规方法,制成中药汤剂,每日1剂,分早晚两次服用,每次煎服150ml,2周为一个疗程,连续治疗3个疗程。
临床试验:
1、选择糖尿病肾病患者160例进行临床观察,其中男80例,女80例,年龄37-75岁,平均年龄58.34岁,病程6-25年,平均17.46年,将160例糖尿病肾病患者分为实验组1-3(每组40例)和对照组40例。患者年龄大小、性别构成和糖尿病病程等在4组分别均衡(P>0.05),具有可比性。
2、糖尿病肾病诊断标准
2.1西医诊断标准参考《中国糖尿病防治指南》:有糖尿病病史,尿微量白蛋白定量30-300mg/24h或尿蛋白定性阳性,排除妊娠、肿瘤、结石、感染、风湿性疾病、心脏病、肝病及原发性肾脏疾病引起的蛋白尿。
2.2、中医诊断标准:早期表现为气虚、头晕目眩、夜尿频数、舌质淡红、脉弦涩;中期可见消瘦乏力、腰膝酸软、头晕耳鸣、小便频数、舌红、脉细数,晚期表现为气短懒言、畏寒肢冷、便溏、下肢水肿、苔薄白或少苔,脉沉细。
3、实验方法:实验组1-3分别对应服用本发明实施例1-3用于治疗糖尿病肾病的中药汤剂,上述中药每日1剂,分早晚两次服用,每次煎服150ml,2周为一个疗程,连续治疗3个疗程。对照组按照标准给予糖尿病饮食、运动、心理疗法,并运用口服阿卡波糖降糖药或(和)胰岛素控制血糖,治疗过程中每2周观察一次实验组1-3和对照组患者临床症状、体征和各项临床生化指标。
4、疗效判定:
显效:尿白蛋白排泄率<20ug/min,体征和症状消失;
有效:尿白蛋白排泄率下降一半以上,体征和症状明显减轻;
无效:尿白蛋白排泄率未下降或下降未达到一半,体征和症状无变化。总有效率包括显效和有效。
采用X2检验,p<0.05差异有统计学意义。
临床试验结果:
表1:治疗2周后效果统计表
分组 | 总人数 | 显效 | 有效 | 无效 | 总有效率 |
实验组1 | 40 | 2 | 7 | 31 | 29% |
实验组2 | 40 | 2 | 10 | 28 | 30% |
实验组3 | 40 | 3 | 9 | 28 | 30% |
对照组 | 40 | 3 | 11 | 26 | 35% |
表2:治疗4周后效果统计表
分组 | 总人数 | 显效 | 有效 | 无效 | 总有效率 |
实验组1 | 40 | 15 | 17 | 8 | 80% |
实验组2 | 40 | 17 | 19 | 4 | 90% |
实验组3 | 40 | 14 | 21 | 5 | 87.5% |
对照组 | 40 | 9 | 20 | 11 | 72.5% |
表3:治疗6周后效果统计表
分组 | 总人数 | 显效 | 有效 | 无效 | 总有效率 |
实验组1 | 40 | 20 | 17 | 3 | 92.25% |
实验组2 | 40 | 25 | 14 | 1 | 97.5% |
实验组3 | 40 | 23 | 15 | 2 | 95% |
对照组 | 40 | 14 | 21 | 5 | 87.5% |
由表1-3可知,实验组1-3和对照组分别治疗2周后,对照组的治疗效果优于实验组1-3;但是随着治疗时间的延长,治疗4周后,实验组2的总有效率提升至90%,实验组1-3的疗效均优于对照组;治疗6周后,实验组2的总有效率高达97.5%,实验组1-3的疗效明显优于对照组。因此,本发明实施例1-3的中药制剂对糖尿病肾病患者均具有明显的治疗效果,其中本发明实施例2制备得到的中药制剂的治疗效果最佳。在治疗过程中,实验组1-3和对照组均未出现明显不良反应,治疗前后血常规、肝功能检查均未见明显异常。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (5)
1.一种用于治疗糖尿病肾病的中药,其特征在于,由以下重量份的原料组分制成:熟地黄20-60份、黄芪20-55份、丹参12-24份、麦冬15-26份、葛根25-35份、茯苓20-30份、灸甘草10-18份。
2.如权利要求1所述的用于治疗糖尿病肾病的中药,其特征在于,由以下重量份的原料组分制成:熟地黄49份、黄芪48份、丹参21份、麦冬17份、葛根26份、茯苓22份、灸甘草11份。
3.如权利要求1所述的用于治疗糖尿病肾病的中药,其特征在于,由以下重量份的原料组分制成:熟地黄56份、黄芪36份、丹参21份、麦冬23份、葛根25份、茯苓24份、灸甘草15份。
4.如权利要求1所述的用于治疗糖尿病肾病的中药,其特征在于,由以下重量份的原料组分制成:熟地黄37份、黄芪46份、丹参17份、麦冬25份、葛根31份、茯苓28份、灸甘草16份。
5.如权利要求1-4任意一项所述的用于治疗糖尿病肾病的中药,其特征在于:所述中药的剂型为溶液剂、片剂、丸剂、颗粒剂、冲剂或者胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810316959.4A CN108578563B (zh) | 2018-04-10 | 2018-04-10 | 一种用于治疗糖尿病肾病的中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810316959.4A CN108578563B (zh) | 2018-04-10 | 2018-04-10 | 一种用于治疗糖尿病肾病的中药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108578563A true CN108578563A (zh) | 2018-09-28 |
CN108578563B CN108578563B (zh) | 2021-02-23 |
Family
ID=63621674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810316959.4A Active CN108578563B (zh) | 2018-04-10 | 2018-04-10 | 一种用于治疗糖尿病肾病的中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108578563B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112274592A (zh) * | 2020-12-09 | 2021-01-29 | 丽江糖去宁生物科技有限公司 | 一种糖尿病治疗及恢复的药食同源代泡茶 |
CN113144070A (zh) * | 2021-04-25 | 2021-07-23 | 河南中医药大学 | 一种用于治疗糖尿病肾病的中药组合物及其制备方法 |
CN113995823A (zh) * | 2021-10-29 | 2022-02-01 | 瑞纳康(北京)生物科技有限公司 | 一种降糖扶胰方及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103142844A (zh) * | 2011-12-06 | 2013-06-12 | 周昌明 | 一种治疗糖尿病肾病的药物组合物 |
CN103623292A (zh) * | 2013-12-24 | 2014-03-12 | 山东省中医药研究院 | 一种治疗糖尿病的中药组合物 |
CN107648451A (zh) * | 2017-10-31 | 2018-02-02 | 上海市普陀区中心医院 | 一种治疗糖尿病肾病的黄芪汤免煎颗粒新剂型及其用途 |
-
2018
- 2018-04-10 CN CN201810316959.4A patent/CN108578563B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103142844A (zh) * | 2011-12-06 | 2013-06-12 | 周昌明 | 一种治疗糖尿病肾病的药物组合物 |
CN103623292A (zh) * | 2013-12-24 | 2014-03-12 | 山东省中医药研究院 | 一种治疗糖尿病的中药组合物 |
CN107648451A (zh) * | 2017-10-31 | 2018-02-02 | 上海市普陀区中心医院 | 一种治疗糖尿病肾病的黄芪汤免煎颗粒新剂型及其用途 |
Non-Patent Citations (2)
Title |
---|
周正华等: ""芪丹地黄汤治疗糖尿病肾病25例"", 《陕西中医》 * |
李德锋等: ""益气养阴活血方治疗糖尿病肾病气阴两虚夹瘀证临床研究"", 《辽宁中医药大学学报》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112274592A (zh) * | 2020-12-09 | 2021-01-29 | 丽江糖去宁生物科技有限公司 | 一种糖尿病治疗及恢复的药食同源代泡茶 |
CN113144070A (zh) * | 2021-04-25 | 2021-07-23 | 河南中医药大学 | 一种用于治疗糖尿病肾病的中药组合物及其制备方法 |
CN113995823A (zh) * | 2021-10-29 | 2022-02-01 | 瑞纳康(北京)生物科技有限公司 | 一种降糖扶胰方及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108578563B (zh) | 2021-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108578563A (zh) | 一种用于治疗糖尿病肾病的中药 | |
CN104983985B (zh) | 一种治疗抑郁症的中药制剂 | |
CN103341092B (zh) | 一种治疗萎缩性阴道炎的散剂制备方法 | |
CN105148210A (zh) | 一种治疗咳嗽的中药及其制备方法 | |
CN103301355A (zh) | 一种慢性肾衰竭结肠透析液制备方法 | |
CN103463593B (zh) | 一种治疗肥胖症的药茶 | |
CN103285284A (zh) | 一种治疗老年性阴道炎的药物组合物 | |
CN103301353A (zh) | 一种治疗萎缩性阴道炎的药物组合物 | |
CN102423394B (zh) | 治疗腰腿疼的药酒 | |
CN103330867A (zh) | 一种治疗老年性阴道炎的散剂制备方法 | |
CN114732889B (zh) | 一种治疗支气管哮喘急性发作期痰浊阻肺证的中药组合物、中药口服制剂 | |
CN101244194B (zh) | 一种治疗瘰疬疾病的中药药物 | |
CN101912584A (zh) | 一种治疗郁症的药物及其制备方法 | |
CN105213751A (zh) | 一种治疗咳嗽的中药组合物 | |
CN106923120A (zh) | 一种含有罗勒益智补脑的维吾尔医养生饮料及其制备方法 | |
CN106139116A (zh) | 一种可防治肥胖ⅱ型糖尿病合并血脂异常的中药组合物 | |
CN105213678A (zh) | 一种清肺、止咳、化痰的中药组合物 | |
CN119386132A (zh) | 一种中药组合物、膏剂及其应用 | |
CN105055694A (zh) | 一种治疗肝郁化火型抑郁症的中药制剂 | |
CN103356984B (zh) | 一种防治女性缺铁性贫血的中药组合物 | |
CN103007083A (zh) | 一种用于治疗痛风的中药组合物及其应用 | |
CN111329927A (zh) | 一种治疗女性特发性水肿的中药 | |
CN118767080A (zh) | 一种治疗肾阴虚腰痛的养血补肾丸 | |
CN101991703B (zh) | 一种治疗梅核气疾病的中药药物 | |
CN103341094A (zh) | 一种治疗外阴鳞状上皮细胞增生的散剂制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231214 Address after: 115000, No. 97, West Donghai Street, Xishi District, China (Liaoning) Pilot Free Trade Zone, Yingkou City, Liaoning Province Patentee after: INCREASE PHARMACEUTICAL (YINGKOU) CO.,LTD. Address before: 453003 Xinxiang Medical College, 601 Jinsui Avenue, Xinxiang City, Henan Province Patentee before: XINXIANG MEDICAL University |